Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A V Ivashchenko

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Eksperimental'Naia I Klinicheskaia Farmakologiia|July 19, 2014
[Preclinical study of the new anti-influenza drug candidate AV0038 (ethyl 2-(dimethylaminomethyl)-5-hydroxy-1-methyl-6-(pyridin-3-yl)-1H-indole-3-carboxylate)]A V Ivashchenko, P M Iamanushkin, O D Mit'kin, et al.
Eksperimental'Naia I Klinicheskaia Farmakologiia|August 24, 2010
[Toxicity of ethyl-3-(8-fluoro-2-methyl-2,3,4,5-tetrahydropyrido[4,3-b]indol-5-yl)-propionate dihydrochloride possessing antiallergic properties]A V Ivashchenko, M G Kadieva, O D Mit'kin, et al.
Eksperimental'Naia I Klinicheskaia Farmakologiia|December 19, 2014
[Antiviral activity in vitro and pharmacokinetics of HCV entry inhibitor AVR560]A V Ivashchenko, P M Iamanushkin, O D Mit'kin, et al.
Eksperimental'Naia I Klinicheskaia Farmakologiia|August 1, 2014
[Preclinical study of AV0012 early stage inhibitor of hepatitis C virus infection: I. In vitro ADME and pharmacokinetics]A V Ivashchenko, P M Iamanushkin, O D Mit'kin, et al.
Eksperimental'Naia I Klinicheskaia Farmakologiia|March 6, 2015
[Preclinical study of safety of the new pharmacological substance AV0012 to treat hepatitis C]A V Ivashchenko, P M Iamanushkin, O D Mit'kin, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Eksperimental'Naia I Klinicheskaia Farmakologiia|July 19, 2014
[Preclinical study of the new anti-influenza drug candidate AV0038 (ethyl 2-(dimethylaminomethyl)-5-hydroxy-1-methyl-6-(pyridin-3-yl)-1H-indole-3-carboxylate)]A V Ivashchenko, P M Iamanushkin, O D Mit'kin, et al.
Eksperimental'Naia I Klinicheskaia Farmakologiia|August 24, 2010
[Toxicity of ethyl-3-(8-fluoro-2-methyl-2,3,4,5-tetrahydropyrido[4,3-b]indol-5-yl)-propionate dihydrochloride possessing antiallergic properties]A V Ivashchenko, M G Kadieva, O D Mit'kin, et al.
Eksperimental'Naia I Klinicheskaia Farmakologiia|December 19, 2014
[Antiviral activity in vitro and pharmacokinetics of HCV entry inhibitor AVR560]A V Ivashchenko, P M Iamanushkin, O D Mit'kin, et al.
Eksperimental'Naia I Klinicheskaia Farmakologiia|August 1, 2014
[Preclinical study of AV0012 early stage inhibitor of hepatitis C virus infection: I. In vitro ADME and pharmacokinetics]A V Ivashchenko, P M Iamanushkin, O D Mit'kin, et al.
Eksperimental'Naia I Klinicheskaia Farmakologiia|March 6, 2015
[Preclinical study of safety of the new pharmacological substance AV0012 to treat hepatitis C]A V Ivashchenko, P M Iamanushkin, O D Mit'kin, et al.
Pageof 2